– Introduction – This article continues to summarize some of the previously publicly disclosed high-quality medical asset projects, covering six major categories of full-track technology platforms:
– Introduction – This article summarizes some of the publicly disclosed high-quality medical asset projects from previous periods, covering six major categories of full-track technology platforms:
Introduction: Currently, the biopharmaceutical industry is at a critical juncture of technological paradigm transformation. Frontier tracks such as exosome drugs, nucleic acid delivery, cell therapy, and
Many clients ask when applying for a patent: “How much does it cost to apply for a patent?” Is there a way to save money? “
💡 The current medical industry is accelerating iteration, with technology research and development, clinical translation, and commercialization processes continuing to accelerate. Medical assets with high barriers,
In 2025, the total amount of authorized transactions for innovative drugs in China will exceed 130 billion US dollars, with over 150 authorized transactions, a significant
Starting from January 1, 2026, the revised “Guidelines for Patent Examination” of the State Intellectual Property Office will officially come into effect, adding exclusive examination chapters
Biopharmaceuticals are accelerating clinical translation, and high-quality medical projects are entering a golden window period for investment, financing, and mergers and acquisitions. This issue selects 6 high-quality
Introduction- Medical and health innovation is accelerating its evolution, cutting-edge technologies continue to break through clinical translation bottlenecks, and high-quality assets are becoming a strategic pivot
Nowadays, the pharmaceutical market is mainly divided into two tracks: small molecule chemical drugs and large molecule biopharmaceuticals, which have vastly different molecular structures, production processes,
